C. Lindgren

发表

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.

S. Riddell, P. Greenberg, S. Forman, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.

S. Riddell, K. Kelly-Spratt, A. Oron, 2017, Blood.

Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.

S. Riddell, P. Greenberg, S. Forman, 2007, Human gene therapy.

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Jinjuan Wang, Xiaojun Qian, D. Maloney, 2012, Blood.

Lymphocyte apheresis for chimeric antigen receptor T‐cell manufacturing in children and young adults with leukemia and neuroblastoma

Francesco Ceppi, Julie R. Park, Navin Pinto, 2018, Transfusion.

Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial.

J. Thompson, C. Collins, D. Lee, 1987, Cancer research.

Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.

J. Thompson, D. Byrd, A. Fefer, 1997, The cancer journal from Scientific American.

Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation.

J. Thompson, M. Benyunes, W. Bensinger, 1994, Bone marrow transplantation.

CD20-speciﬁc adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

D. Maloney, S. Riddell, P. Greenberg, 2012 .

IL-2-BASED CONSOLIDATIVE IMMUNOTHERAPY AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION

John A Thompson, M. Benyunes, A. Fefer, 1993 .

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.

J. Thompson, C. Collins, W. Shuman, 1989, Cancer research.

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.

J. Thompson, C. Collins, D. Lee, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

M. Jensen, Lauren A Huang, O. Finney, 2018, Blood.

Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients.

J. Thompson, P. Greenberg, J. Treisman, 1990, Cancer research.

Use of IL-2 and Lymphocytes Following Bone Marrow Transplantation

John A Thompson, M. Benyunes, A. Fefer, 1992 .

Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.

J. Thompson, John A Thompson, T. Cox, 1989, Cancer research.

Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.

J. Thompson, S. Gillis, A. Fefer, 1989, Cancer research.

Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.

P. Lange, J. Thompson, C. Collins, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

F. Appelbaum, W. Bensinger, A. Fefer, 1997, Bone Marrow Transplantation.

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

Jinjuan Wang, Brent L Wood, Xiaojun Qian, 2008, Blood.

Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia.

J. Thompson, F. Appelbaum, John A Thompson, 1996, Blood.

CD20-specific T cells mantle cell lymphoma using genetically modified autologous Adoptive immunotherapy for indolent non-Hodgkin lymphoma and

B. Wood, S. Riddell, P. Greenberg, 2011 .

Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy.

Jonathan H. Esensten, N. Zhang, P. Hanley, 2020, Cytotherapy.

Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects

John A Thompson, A. Fefer, E. Bonnem, 2004, Cancer Immunology, Immunotherapy.

Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.

J. Thompson, M. Benyunes, A. Fefer, 1993, Acta haematologica.

CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results

D. Maloney, S. Riddell, P. Greenberg, 2012 .

results antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial CD20-specific adoptive immunotherapy for lymphoma using a chimeric

D. Maloney, S. Riddell, P. Greenberg, 2012 .

53. Preliminary Results of a Pilot Phase I Clinical Trial of Adoptive Immunotherapy for B Cell Lymphoma Using CD8+ T Cells Genetically Modified To Express a Chimeric T Cell Receptor Recognizing CD20

S. Riddell, P. Greenberg, J. Pagel, 2006 .

bone marrow transplantation for children with acute leukemia Phase I trial of interleukin-2 after unmodified HLA-matched sibling

F. Appelbaum, M. Benyunes, J. Sanders, 2011 .

Modified manufacturing process modulates CD19CAR T-cell engraftment fitness and leukemia-free survival in pediatric and young adult subjects.

M. Jensen, M. Pulsipher, Julie R. Park, 2022, Cancer immunology research.

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Amanda M Li, Josh Gustafson, M. Jensen, 2021, Blood.

Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.

Amanda M Li, V. Wu, M. Jensen, 2020 .

Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.

J. Thompson, M. Benyunes, W. Bensinger, 1997, The cancer journal from Scientific American.

T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse

K. Kelly-Spratt, A. Oron, M. Jensen, 2014 .

Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.

J. Thompson, John A Thompson, M. Benyunes, 1995, Bone marrow transplantation.

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

M. Jensen, M. Pulsipher, Julie R. Park, 2019, Blood.

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

M. Jensen, Julie R. Park, Colleen Annesley, 2019, Blood.

Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.

J. Thompson, A. Fefer, C. Lindgren, 1993, Experimental hematology.

Prolonged functional persistence of CD19CAR t cell products of defined CD4:CD8 composition and transgene expression determines durability of MRD-negative ALL remission.

A. Oron, M. Jensen, O. Finney, 2016 .

Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4.

J. Thompson, John A Thompson, A. Fefer, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.